Peptipedia
CognitiveNot FDA ApprovedClinical Trials

Cerebrolysin

Also known as FPE 1070

A neuropeptide mixture derived from porcine brain tissue, indicated for neurological conditions including stroke recovery, cognitive decline, and traumatic brain injury.

Approved in 40+ countries - Not FDA approved
CompareFind Vendors

Regulatory Pathway

Preclinical
Phase I
Phase II
Phase III
Phase IV
Approved

Dosing Protocol

Typical Dose

5-10 mL IV/IM daily for 10-20 days

Frequency

Daily during treatment cycles

Duration

10-20 day cycles

Community-reported dosing. Individual results vary. Not a medical recommendation.
Typical community protocol: 5-10 mL IV/IM daily for 10-20 days via Intravenous or intramuscular injection, Daily during treatment cycles. Dose range: 5-30 mL per day. Duration: 10-20 day cycles.

Timing & Administration

Administer via Intravenous or intramuscular injection. Frequency: Daily during treatment cycles.

Mechanism of Action

Contains neurotrophic factors that mimic BDNF, NGF, and CNTF activity. Enhances neuroplasticity, protects neurons from excitotoxicity, promotes neurogenesis, and improves synaptic function.

Research Summary

Evidence level: clinical trials. Clinical status: Approved in 40+ countries - Not FDA approved.

Side Effects & Safety

Important Warnings

  • Not approved in the US
Dizziness
headache
nausea
agitation
confusion
anaphylactic shock (rare)

References

No references available.

Related Peptides

Browse all →
SelankCognitive

A synthetic peptide derived from tuftsin, an immunomodulatory peptide. Approved in Russia for anxiety and nootropic effects.

View profile
SemaxCognitive

Synthetic peptide derived from ACTH (4-10) fragment with added Pro-Gly-Pro sequence. Used clinically in Russia for stroke, traumatic brain injury, and cognitive disorders.

View profile
DihexaCognitive

A potent cognitive-enhancing peptide derived from angiotensin IV. Reported to be 10 million times more potent than BDNF at promoting synaptogenesis.

View profile